Aveo Licenses Antibody to Novartis for Treatment of Cachexia

19.08.2015 - US biopharmaceutical company Aveo Oncology has entered into a global license agreement with Novartis for its AV-380 and related antibodies. AV-380 is a potent inhibitory antibody...